Yanhong Deng
Sixth Affiliated Hospital, Sun Yat-sen University · Sun Yat-sen University · The Six Affiliated Hospital,Sun Yat-sen University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
24
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in colorectal cancer
62
PubMed author-name match
Trials
Studies that name Yanhong Deng as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:38 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07809893 · Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer PatientsSun Yat-sen University · recruiting · Colorectal Cancer · principal investigator
- Ph3NCT07729605 · FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRCSun Yat-sen University · not yet recruiting · Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC) · principal investigator
- Ph1/Ph2NCT06434090 · Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal CancerSun Yat-sen University · unknown · Colorectal Cancer · principal investigator
- N/ANCT06036862 · Utilization of Transanal Endoscopy in the Treatment of Anastomotic StenosisSun Yat-sen University · recruiting · Anastomotic Stenosis · principal investigator
- Ph2NCT05959356 · Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal CancerSun Yat-sen University · recruiting · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT05933980 · Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal CancerSun Yat-sen University · unknown · Colorectal Cancer, Liver Metastases, MSS · principal investigator
- Ph1/Ph2NCT05775900 · Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal CancerSun Yat-sen University · completed · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT05571644 · Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal CancerSun Yat-sen University · recruiting · Colorectal Cancer · principal investigator
- Ph2NCT05472948 · Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaSun Yat-sen University · recruiting · Adenocarcinoma of Small Intestine, Appendix Carcinoma, Metastatic · principal investigator
- Ph3NCT05427669 · Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)Yanhong Deng · not yet recruiting · Colorectal Cancer · principal investigator
- Ph1NCT04930354 · ECP-1014 Treatment for Patients With Solid Tumor CancersEuclises Pharmaceuticals, Inc. · unknown · Solid Tumor · principal investigator
- Ph3NCT04338191 · mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal CancerSun Yat-sen University · unknown · Colorectal Cancer · principal investigator
- Ph3NCT04230187 · Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal CancerYanhong Deng · active not recruiting · Colorectal Cancer · principal investigator
- Ph2NCT04030260 · Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal CancerSun Yat-sen University · unknown · Colorectal Cancer Metastatic, MSS · principal investigator
- Ph2NCT03926338 · Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal CancerSun Yat-sen University · recruiting · Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) · principal investigator
- Ph2NCT03638297 · PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal CancerSun Yat-sen University · unknown · Colorectal Cancer · principal investigator
- Ph2NCT02915965 · A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell CarcinomaSun Yat-sen University · unknown · Stage II and III Esophageal Squamous Cell Carcinoma · principal investigator
- Ph3NCT02909478 · Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal CancerSun Yat-sen University · completed · Chemotherapy-induced Nausea and Vomiting, Colorectal Cancer · principal investigator
- Ph2NCT02887313 · FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Real World StudySun Yat-sen University · unknown · Rectal Cancer · principal investigator
- Ph3NCT02572141 · FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)Sun Yat-sen University · active not recruiting · Colon Cancer · principal investigator
- Ph2NCT02350530 · FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-typeSun Yat-sen University · completed · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT02128425 · FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal CancerSun Yat-sen University · unknown · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT02063529 · FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal CancerSun Yat-sen University · completed · Metastatic Colorectal Cancer · principal investigator
- Ph2NCT01880658 · Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal CancerSun Yat-sen University · unknown · Colorectal Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:38 UTC. The ranking covers the 200 most relevant of 62 PubMed records, and a shared surname and initials can bring in a namesake. All 62 on PubMed
- 379 citationsRCR 11.7
- 329 citationsRCR 11.8
- Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial.J Clin Oncol · 2019294 citationsRCR 12.4
- Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.Lancet Gastroenterol Hepatol · 2022265 citationsRCR 16.1
- Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.Cancer Invest · 2003137 citationsRCR 2.2
- Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.J Hematol Oncol · 2021133 citationsRCR 6.3
- Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.Dis Colon Rectum · 2016128 citationsRCR 5.8
- 120 citationsRCR 3.8
- Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer.J Clin Oncol · 2000105 citationsRCR 1.7
- Impact of Long-Course Neoadjuvant Radiation on Postoperative Low Anterior Resection Syndrome and Quality of Life in Rectal Cancer: Post Hoc Analysis of a Randomized Controlled Trial.Ann Surg Oncol · 2019102 citationsRCR 5.4